Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis

Published:2022-01-19 Issue:1 Volume:60 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Whitfield Michael G.¹²³^ORCID,Engelthaler David M.⁴^ORCID,Allender Christopher⁴,Folkerts Megan⁴,Heupink Tim H.²,Limberis Jason⁵,Warren Robin M.³,Van Rie Annelies²,Metcalfe John Z.⁵

Affiliation:

1. National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK

2. Family Medicine and Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

3. South African Medical Research Council Centre for Tuberculosis Research/DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Stellenbosch University, South Africa

4. Translational Genomics Research Institute, Flagstaff, Arizona, USA

5. University of California San Francisco, San Francisco, California, USA

Abstract

Pyrazinamide is an important component of both drug-susceptible and drug-resistant tuberculosis treatment regimens. Although approximately 50% of rifampin-resistant isolates are also resistant to pyrazinamide, pyrazinamide susceptibility testing is not routinely performed due to the challenging nature of the assay.

Funder

Fonds Wetenschappelijk Onderzoek

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01907-21

Reference48 articles.

1. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis

2. Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 Months